DUXARIL
Content
Almitrine bismesylate 30 mg, Raubasine 10 mg.
Description
Each tablet
contains almitrine 30 mg and raubasine 10 mg. It also contains the
following excipients: Cornstarch, ethylcellulose, glycerin, hydroxypropyl
methylcellulose, lactose, CI natural red 4, titanium dioxide, polyethylene
glycol, povidone, colloidal silicon dioxide, magnesium stearate and talc.
Actions
Antihypoxic drug.
Pharmacology: The actions of
almitrine-raubasine have been demonstrated in animals, in numerous models
of experimental cerebral hypoxia, as well as in man, in whom
pharmacoclinical studies have demonstrated the following:
Increase in the arterial partial pressure
of oxygen (PaO2);
Increase in the arterial saturation of oxygen (SaO2);
Decrease in the arterial desaturation during effort, a dynamic control
considered as one of the best techniques currently available to assess the
efficacy of an antihypoxic molecule;
Increase of the blood level of
2,3-diphosphoglycerate, a factor of oxygen availability in the arterial
blood;
Increase in the metabolism of the cerebral
tissue as demonstrated, during the glucose test, by the analysis of the
cortical activity.
The improvement in the blood gas parameters
under almitrine-raubasine is linked to an improvement of the efficacy of
the alveolar capillary exchange mechanism without modification of the
ventilatory parameters.
These properties explain the activity of
almitrine-raubasine on the psychobehavioural disturbances in the elderly.
Pharmacokinetics: Almitrine is
rapidly absorbed and the plasmatic peak is obtained within 3 hrs after
oral administration. Almitrine and its metabolites are mainly excreted
through the biliary tract. The elimination is, thus, mainly through the
faeces. After single administration, the half-life is between 40-80 hrs;
it is 30 days after repeated administration. The binding to protein is
high (>99%).
Raubasine is rapidly absorbed, and the
plasmatic peak is obtained 1-2 hrs after oral administration. After single
administration, the half-life is between 7-15 hrs; it is 11 hrs after
repeated administration.
Indication
Pathological loss
of cognitive function related to cerebral aging. Chorioretinal disorders
of ischemic origin. Cochleovestibular disorders of ischemic origin. Early
& late sequelae of CVA.
Dosage
2 tab daily in 2
divided doses.
Contraindication
Avoid concurrent
administration w/ MAOIs, almitrine.
Special
Precaution Pregnancy.
Occurrence of neurological symptoms (prickling, formication, numbness)
should lead to w/drawal. The treatment does not eliminate the need for
specific treatment of hypertension.
Adverse
Reaction Have
been occasionally reported during long-term treatment: wt loss, peripheral
neuropathy should lead to treatment w/drawal. Mild GI disorders, sleep
disturbances, drowsiness, agitation, anxiety, palpitation, dizziness.
Side
Effects
Drug
Interaction MAOIs,
other almitrine-containing prep.
Presentation
& Packing
| Form |
Packing
/ Price |
Photo |
| tab |
100's |
|
|
